MedTrace Logo

Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma

NCT00815308 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2011-02-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the treatment of locally advanced esophageal squamous cell carcinoma (ESCC)with cetuximab in combination with paclitaxel, cisplatin and radiation improve clinical outcomes.

Conditions

  • Esophageal Cancer

Interventions

DRUG

cetuximab (Erbitux)

Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)

DRUG

Paclitaxel

Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)

DRUG

Cisplatin

Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)

RADIATION

Radiation

Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • Hebei Fourth Hospital

    collaborator UNKNOWN

  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • The Affiliated Cancer Hospital of Zhengzhou University

    collaborator UNKNOWN

  • West China Hospital

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    lead OTHER

Principal Investigators

  • Jin Ming Yu, PH.D, M.D · Shandong Cancer Hospital and Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00815308 on ClinicalTrials.gov